Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
September 21, 2021
Assignee:
NOVARTIS AG
Inventors:
Christoph Heusser, James Rush, Karen Vincent
Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
September 7, 2021
Assignees:
NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
September 7, 2021
Assignee:
Novartis AG
Inventors:
Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
September 7, 2021
Assignee:
NOVARTIS AG
Inventors:
Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
Type:
Grant
Filed:
March 6, 2020
Date of Patent:
September 7, 2021
Assignee:
NOVARTIS AG
Inventors:
Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
Type:
Grant
Filed:
May 10, 2019
Date of Patent:
August 31, 2021
Assignee:
NOVARTIS AG
Inventors:
Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
Abstract: A medical device (100) comprises a container receiver unit (110) configured to receive and hold a container (120), wherein the container (120) accommodates a pharmaceutical product (125) and comprises a first communication tag (130) configured to store information regarding the pharmaceutical product (125), a reader unit (140) configured to wirelessly read the information from the first communication tag (130), and a control unit (150) configured to control the medical device (100) based on the information read from the first communication tag (130). The medical device (100) further comprises an opening or a transparent window (165) allowing to at least partially see from the outside the container (120) inserted into the container receiver unit (110), wherein the reader unit (140) comprises a first antenna unit (142, 144), and the container (120) inserted into the container receiver unit (110) is located between (i) the opening or the transparent window (165) and (ii) the first antenna unit (142, 144).
Type:
Grant
Filed:
February 5, 2018
Date of Patent:
August 31, 2021
Assignee:
NOVARTIS AG
Inventors:
Alain Schmidlin, Mario Iobbi, Erich Studer, Andrew Bryant, Chinmay Deodhar, Rajan Patel, Samuel Coendet, Vivek Gajera, Prakash Parmar
Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
August 31, 2021
Assignee:
Novartis AG
Inventors:
Päivi M. Paldánius, Wolfgang Kothny, James E. Foley, David R. Matthews, Michael Stumvoll, Stefano Del Prato
Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
Type:
Grant
Filed:
June 18, 2020
Date of Patent:
August 24, 2021
Assignee:
Novartis AG
Inventors:
Ralph Tiedt, Christian Chatenay-Rivauday, Moriko Ito, Mikhail Akimov, Bin Peng, Ying Gong
Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
August 24, 2021
Assignee:
Novartis AG
Inventors:
Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin Robert Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
August 24, 2021
Assignee:
Novartis AG
Inventors:
Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
Type:
Grant
Filed:
July 1, 2017
Date of Patent:
August 24, 2021
Assignees:
CHINOOK THERAPEUTICS, INC., NOVARTIS AG
Inventors:
David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
August 24, 2021
Assignee:
NOVARTIS AG
Inventors:
Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger